Bradley D. McDowell

Dr. Bradley D. McDowell

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Pituitary
Verified
Journal Article
Closed access
PDF file
BMBradley D. McDowell
Bradley D. McDowell
RWRobert B. Wallace
Robert B. Wallace
RCRyan M. Carnahan
Ryan M. Carnahan
ECElizabeth Chrischilles
Elizabeth Chrischilles
CLCharles F. Lynch
Charles F. Lynch
JSJanet A. Schlechte
Janet A. Schlechte

6 December 2002 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
DMDavid J. Moser
David J. Moser
MBMichelle L. Benjamin
Michelle L. Benjamin
JBJohn D. Bayless
John D. Bayless
BMBradley D. McDowell
Bradley D. McDowell
JPJane S Paulsen
Jane S Paulsen
AAArnold E. Andersen
Arnold E. Andersen

13 July 2016 in BMC Urology
Verified
Journal Article
Open access
PDF file
KBKerri T. Barnes
Kerri T. Barnes
BMBradley D. McDowell
Bradley D. McDowell
ABAnna Button
Anna Button
BSBrian J Smith
Brian J Smith
CLCharles F. Lynch
Charles F. Lynch
AGAmit Gupta
Amit Gupta
To validate the association between obesity and penile cancer at a population level, we conducted a matched case–control study linking the Iowa Department of Motor Vehicles Drivers’ License Database (DLD) with cancer surveillance data collected by the State Health Registry of Iowa (SHRI). All men diagnosed with invasive penile squamous cell carcinoma from 1985 to 2010 were identified by SHRI. Two hundred sixty-six cancer cases and 816 cancer-free male controls, selected from the Iowa DLD, were matched within 5-year age and calendar year strata. Body mass index (BMI) was calculated using self-reported height and weight from the DLD. Conditional logistic regression was used to evaluate the association between BMI and the risk of developing invasive penile cancer. Obesity was significantly associated with an increased risk of developing penile cancer. For every five-unit increase in BMI the risk of invasive penile cancer increased by 53 % (OR 1.53, 95 % CI 1.29-1.81, p < 0.0001). We previously reported an association between obesity and higher risk of invasive penile cancer and advanced cancer stage at diagnosis in a hospital-based retrospective study. This population-based study confirms an association between obesity and invasive penile cancer.

6 December 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EHEmma Herbach
Emma Herbach
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
RCRyan M. Carnahan
Ryan M. Carnahan
BMBradley D. McDowell
Bradley D. McDowell
BABryan Allen
Bryan Allen
ECElizabeth Chrischilles
Elizabeth Chrischilles
Background: We compared cardiac outcomes for surgery‐eligible patients with stage III non‐small‐cell lung cancer treated adjuvantly or neoadjuvantly with chemotherapy versus chemo‐radiation therapy in the Surveillance, Epidemiology and End Results‐Medicare database. Methods and Results: Patients were age 66+, had stage IIIA/B resectable non‐small‐cell lung cancer diagnosed between 2007 and 2015, and received adjuvant or neoadjuvant chemotherapy or chemo‐radiation within 121 days of diagnosis. Patients having chemo‐radiation and chemotherapy only were propensity‐score matched and followed from day 121 to first cardiac outcome, noncardiac death, radiation initiation by patients who received chemotherapy only, fee‐for‐service enrollment interruption, or December 31, 2016. Cause‐specific hazard ratios (HRs) and competing risks subdistribution HRs were estimated. The primary outcome was the first of these severe cardiac events: acute myocardial infarction, other hospitalized ischemic heart disease, hospitalized heart failure, percutaneous coronary intervention/coronary artery bypass graft, cardiac death, or urgent/inpatient care for pericardial disease, conduction abnormality, valve disorder, or ischemic heart disease. With median follow‐up of 13 months, 70 of 682 patients who received chemo‐radiation (10.26%) and 43 of 682 matched patients who received chemotherapy only (6.30%) developed a severe cardiac event ( P =0.008) with median time to first event 5.45 months. Chemo‐radiation increased the rate of severe cardiac events (cause‐specific HR: 1.62 [95% CI, 1.11–2.37] and subdistribution HR: 1.41 [95% CI, 0.97–2.04]). Cancer severity appeared greater among patients who received chemo‐radiation (noncardiac death cause‐specific HR, 2.53 [95% CI, 1.93–3.33] and subdistribution HR, 2.52 [95% CI, 1.90–3.33]). Conclusions: Adding radiation therapy to chemotherapy is associated with an increased risk of severe cardiac events among patients with resectable stage III non‐small‐cell lung cancer for whom survival benefit of radiation therapy is unclear.

19 March 2003 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
BMBradley D. McDowell
Bradley D. McDowell
DMDavid J. Moser
David J. Moser
KFKarin Ferneyhough
Karin Ferneyhough
WBWayne A. Bowers
Wayne A. Bowers
AAArnold E. Andersen
Arnold E. Andersen
JPJane S Paulsen
Jane S Paulsen

1 October 2019 in Urology
Verified
Journal Article
Closed access
CTConrad M. Tobert
Conrad M. Tobert
KNKenneth G. Nepple
Kenneth G. Nepple
BMBradley D. McDowell
Bradley D. McDowell
MCMary E. Charlton
Mary E. Charlton
SMSarah L. Mott
Sarah L. Mott
BEBrandon Erickson
Brandon Erickson